Allograft Inflammatory Factor 1 expression in cDC1 is required to direct Tbet—driven T cell immunity to defend against intracellular pathogens in vivo 2256292
Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
Findings identify AIF1 as a critical regulator of cDC1 immunogenic identity and protective T cell immunity to intracellular infection, defining a pathway where AIF1 loss reprograms DC—T cell communication toward a regulatory, non-protective outcome.
Abstract
Allograft Inflammatory Factor‑1 (AIF1) is a calcium‑binding protein enriched in conventional dendritic cells, with selective expression in cDC1. We hypothesized that AIF1 programs cDC1 immunity to intracellular pathogens by sustaining their activation and T cell‑priming capacity.
To directly address, AIF1 was selectively deleted in CD11c+ cells prior to infection with the intracellular or extracellular pathogens in vivo. DC and T cell subsets were then analyzed by multiparametric flow cytometry. Additionally Single-cell RNA sequencing (scRNA-seq) under steady-state conditions was analyzed by differential expression and gene set enrichment (GSEA).
Conditional deletion of AIF1 in DCs resulted in a modest (∼20%) reduction of cDC1, without affecting cDC2 populations, indicating a partial lineage dependency. During infection with intracellular pathogens Listeria monocytogenes and LCMV, AIF1‑deficient cDC1 showed impaired activation and defective pathogen control, leading to markedly reduced CD4+ T cell activation, loss of Th1 polarization (CD4+T‑bet+), and diminished CD8+CD54+GranzymeB+ cytotoxic responses. In contrast, infection with extracellular pathogens Helicobacter pylori and Nippostrongylus brasiliensis, eliciting Th2-biased immunity, induced no observable impairment in T cell responses. This aligns with AIF1’s unique expression within cDC1, but not cDC2.
These findings identify AIF1 as a critical regulator of cDC1 immunogenic identity and protective T cell immunity to intracellular infection, defining a pathway where AIF1 loss reprograms DC—T cell communication toward a regulatory, non-protective outcome.
National Institutes of Health (NIH)
Classical and Non-Classical Antigen Presenting Cells (APC)
A dominant mechanism of chemoimmunotherapy resistance in PDAC is the robust infiltration and persistence of neutrophilic or polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Interleukin-1 receptor accessory protein (IL1RAP) is the co-receptor for the IL-1 superfamily cytokines which drive inflammato...
Harper M. Marsh, Andrew Adams, H. Amirian et al.· Cancer Research· 0 citations
Chronic or persistent T cell activation is widely thought to culminate in T cell exhaustion, yet how autoreactive CD8⁺ T cells remain functionally intact despite sustained self-antigen exposure is poorly understood. In chronic infection and cancer this durability is attributed to stem-like, TCF1⁺ PD-1⁺ progenitor-exhau...
Kai-Yuan Hao, Sofia G. Baptista, Aurora Beaumond et al.· bioRxiv· 0 citations
Immune checkpoint blockade (ICB) provides durable therapeutic responses across multiple cancer types. Although crosstalk between T cells and conventional type 1 dendritic cells (cDC1s) is essential, the contribution of other antigen-presenting cells (APCs) to ICB-induced tumor rejection remains unclear. To address...
Hitoki Arisato, Takurou Noguchi, Akihiko Shiiya et al.· Cancer Immunology and Immuno...· 0 citations
Combined TNF and JAK inhibition as an effective therapeutic strategy for TBK1 deficiency is supported and cytotoxic lymphocytes are the primary drivers of aberrant cell death through a T cell-myeloid axis dependent on TNF/IFN-γ synergism.
Xu Han, Jialin Dai, Ji-Hong Xiao et al.· Cell Death & Disease· 0 citations
T cells (Tregs) maintain immune tolerance, yet how they selectively eliminate cognate CD4+ effector T cells remains unclear. We propose a co-activation-dependent elimination mechanism, conceptually akin to synthetic lethality. Using in vitro co-cultures, we show that simultaneous peptide-MHC II recognition by Tregs and...
Yan-Yu Ye, Hao-Yue Zheng, Jia-Qi Duan et al.· Cell Reports· 0 citations
CD8
+
T cells play a crucial role in anti-tumor immunity; however, their functionality is compromised by exhaustion driven by chronic antigen exposure, poor tumor microenvironment, and metabolic dysfunction. Activated CD8
+
T cells undergo extensive proteomic remodeling, which includes the induction of the IRE1-X...
Keith A. Nair, Jessica Lee, Olivia Zaleski et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.